术中局部植人5—氟脲嘧啶缓释剂对结直肠癌化疗的临床研究  

Clinical study of chemotherapy on colorectal cancer patients with Fluorouracil Sustained Release during operation

作　　者：魏忠[1] 傅斌生[1] 赵旭辉[1] 戴寅[1] 谢钊[1] 

机构地区：[1]安徽省肿瘤医院(安徽省立医院分院)普外科,合肥230031

出　　处：《安徽医学》2007年第2期111-113,共3页Anhui Medical Journal

摘　　要：目的探讨结直肠癌患者术中腹腔植入5—氟脲嘧啶缓释剂(中人氟安)化疗的植入位置,用药的剂量以及安全性。方法32例结直肠癌患者随机分成三组,将不同剂量的5-FU缓释剂(400mg,600mg,800mg及其以上)在术中按其肿瘤部位植入或撒入可能有淋巴结转移的区域和可疑亚临床肿瘤病灶区域。观察患者术后2周的不良反应,了解剂量和安全性的关系。结果术后2周连续观察患者未发现术中使用5-FU缓释剂对手术恢复有不良影响,也无严重的全身不良反应和术后并发症。不同剂量组的不良反应无显著差异,个别剂量达到1000mg。结论结直肠癌术中植入5-FU缓释剂对结直肠癌的化疗具有良好的安全性。Objective To evaluate the effect of a neoadjunvant chemotherapy with 5 - Fluoururacil Sustained Release for Implant （5 -FuSRI） implanted in abdominal cavity of the patients with colorectal cancer during operation. Methods 32 patients diagnosed with eoloreetal cancer were randomly divided into the low - dose group （400 rag） （ n = 10）, the medium - dose group （600 rag）（ n = 11 ） , and the high- dose group （≥800 mg）（ n = 11 ）. 5 -FuSRI of various dose were implanted into the position of the tumor and likely lymphatic metastasis subclinicly during operation. Adverse reaction was observed during the 2 weeks postoperatively in order to evaluate the relation between dose and security. Results During the observation of 2 weeks, 5 - FuSRI had not any side effect on the recovery of postoperative patients. No adverse reaction and postoperative complications were found in all patients. There were not differences significantly among adverse reactions in various dose groups. Conclusion The treatment of 5 - FuSRI implanted in abdominal cavity was safe.

关 键 词：5-氟脲嘧啶 结肠直肠肿瘤 化学疗法 

分 类 号：R735.3[医药卫生—肿瘤]